We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

104 hedge funds and large institutions have $138M invested in VYNE Therapeutics in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

5% more capital invested

Capital invested by funds: $132M → $138M (+$6.25M)

0.07% more ownership

Funds ownership: 0.66% → 0.73% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 105 → 104 (-1)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

Holders
104
Holders Change
-1
Holders Change %
-0.95%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
37
Reduced
23
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.74M
2
DAM
Deltec Asset Management
New York
+$3.66M
3
Two Sigma Investments
Two Sigma Investments
New York
+$1.05M
4
Squarepoint
Squarepoint
New York
+$874K
5
State Street
State Street
Massachusetts
+$866K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$1.54M
2
MIM
Monashee Investment Management
Massachusetts
-$581K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$352K
4
Morgan Stanley
Morgan Stanley
New York
-$277K
5
SSA
Schonfeld Strategic Advisors
New York
-$256K
Name Holding Trade Value Shares
Change 		Change in
Stake
PHK
101
Point72 Hong Kong
Hong Kong
$1K +$1K +8 New
AIG
102
American International Group
New York
$133 -$4.27K -34 -3%
MIM
103
Monashee Investment Management
Massachusetts
– -$581K -4,861 Closed
Point72 Asset Management
104
Point72 Asset Management
Connecticut
– -$352K -2,949 Closed
HighTower Advisors
105
HighTower Advisors
Illinois
– -$175K -1,448 Closed
Jane Street
106
Jane Street
New York
– -$164K -1,375 Closed
MIM
107
MetLife Investment Management
New Jersey
– -$119K -993 Closed
MLICM
108
Metropolitan Life Insurance Company (MetLife)
New York
– -$81.4K -681 Closed
OWP
109
Old Well Partners
North Carolina
– -$74K -622 Closed
Millennium Management
110
Millennium Management
New York
– -$70 -584 Closed
SO
111
STRS Ohio
Ohio
– -$60K -504 Closed
AIM
112
Alambic Investment Management
California
– -$25K -211 Closed
Qube Research & Technologies (QRT)
113
Qube Research & Technologies (QRT)
United Kingdom
– -$22K -186 Closed
RJFSA
114
Raymond James Financial Services Advisors
Florida
– -$21K -178 Closed
KWMG
115
King Wealth Management Group
Florida
– -$19K -159 Closed
Principal Financial Group
116
Principal Financial Group
Iowa
– -$19K -157 Closed
DTL
117
Dynamic Technology Lab
Singapore
– -$18K -152 Closed
T. Rowe Price Associates
118
T. Rowe Price Associates
Maryland
– -$17K -143 Closed
CB
119
CNB Bank
Pennsylvania
– -$2K -14 Closed
APWA
120
Atlas Private Wealth Advisors
New Jersey
– -$1K -5 Closed
Daiwa Securities Group
121
Daiwa Securities Group
Japan
– +$503 +4 New
1 2 3 4
5

VYNE Hedge Fund Activity: Q4 2020 in Review

104 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2020, worth a combined $138M — up 4.7% from $132M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VYNE and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 37 added.

The largest buyer was BlackRock, adding an estimated $3.74M. The largest seller was Vivo Capital, cutting an estimated $1.54M.

  • 104 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2020, down from 105 in Q3 2020.
  • Funds reported $138M of VYNE Therapeutics stock for Q4 2020, up 4.7% quarter-over-quarter.
  • 18 funds opened new VYNE Therapeutics positions in Q4 2020 and 19 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.74M added.
  • The largest VYNE Therapeutics seller in Q4 2020 was Vivo Capital, an estimated $1.54M sold.

Based on aggregated 13F filings for Q4 2020.